[The prognostic factors of early mortality in bone marrow transplantation in patients with chronic myeloid leukemia].
BACKGROUND
The use of bone marrow transplantation (BMT) in leukemia treatment is associated with high early morbid-mortality rates. Therefore, to identify morbid-mortality risk factors in this setting can be useful to improve therapeutic ratio.


METHODS
We studied 15 variables in 46 patients with chronic myeloid leukemia (CML) treated with cyclophosphamide, total body irradiation (TBI) and allogeneic BMT. A multivariant analysis with an unconditional logistic regression model was used.


RESULTS
Variables found to be related with early mortality included general state of health and acute graft versus host disease. Patients with a Karnofsky index (KI) between 60% and 80% had a higher risk of early death than those with a KI between 90 and 100%. Patients who developed severe (grade II-IV) acute graft versus host disease (AGVHD), had a relative risk of 15.62 (IC 95%: 3.16-77.34) compared with those who do not. Time between diagnosis and BMT contributed to the creation of the mathematical model without reaching statistical significance.


CONCLUSIONS
In this series and in the range of the parameters analysed, general state of health according to KI, and the appearance of severe AGVHD are the variables related with a higher risk of early mortality.
Algara
M
M
Servicio de Radioterapia, Hospital de L'Esperança, Barcelona.
Valls
A
A
Ruiz
V
V
Carreras
E
E
Sierra
J
J
Grañena
A
A
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000401:mortality*; D002423:Cause of Death; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D017567:Karnofsky Performance Status; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality* / Q000628:therapy*; D008297:Male; D015999:Multivariate Analysis; D011379:Prognosis; D013997:Time Factors
Factores pronósticos de mortalidad precoz en el trasplante de médula ósea en pacientes afectos de leucemia mieloide crónica.